Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer

Sponsor
Fujian Medical University
Study ID
NCT04195828
Phase
PHASE2
Status
Completed

Conditions

  • Advanced Gastric Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Camrelizumab — DRUG
    Camrelizumab One course will last 21 days.Given once every 3 weeks at a dose of 200 mg.
  • Apatinib Mesylate — DRUG
    Apatinib One course will last 21 days.Oral administration at a dose of 250 mg everyday。
  • nab-paclitaxel — DRUG
    nab-paclitaxel One course will last 21 days。Given twice every 3 weeks at a dose of 125 mg/m2.
  • S1 — DRUG
    S-1 was calculated according to body surface area , P.O., bid, d1-d14。And the dosage according body surface area:\<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; \>1.5m2, 60mg every time

Study Details

To evaluate the clinical efficacy and safety of camrelizumab combined with apatinib mesylate, nab-paclitaxel and S-1

Key Dates

Start date
Jun 18, 2020
Status verified
Mar 2025
Primary completion
Jul 22, 2022
Completion
Mar 24, 2025

Study Design

Enrollment
106 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Camrelizumab + Apatinib + nab-paclitaxel +S-1
    Camrelizumab combined with Apatinib mesylate tablets, nab-paclitaxel and S-1 in the treatment of locally advanced gastric cancer
  • Active Comparator: nab-paclitaxel +S-1
    nab-paclitaxel and S-1 in the treatment of locally advanced gastric cancer

Primary Outcome Measure

major pathological response [ Time Frame: 4 months ]

Related Studies